Discontinued Product

ACPC (Cat. No. 0260) has been withdrawn from sale for commercial reasons.
Description: Partial NMDA agonist, acts glycine site
Chemical Name: 1-Aminocyclopropanecarboxylic acid
Literature (5)

Biological Activity for ACPC

NMDA receptor agonist acting at the glycine site.

Technical Data for ACPC

M. Wt 101.1
Storage Store at RT
CAS Number 22059-21-8

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for ACPC

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for ACPC

References are publications that support the biological activity of the product.

Clos et al (1996) Effect of 1-aminocyclopropanecarboxylic acid on N-MthD.-aspartate - stimulated [3H]-noradrenaline release in rat hippocampal synaptosomes. Br.J.Pharmacol. 118 90 PMID: 8799560

Hood et al (1989) 1-Aminocyclobutane-1-carboxylic acid (ACBC): a specific antagonist of the NMDA receptor coupled glycine receptor. Eur.J.Pharmacol. 161 281 PMID: 2542048

Nadler et al (1988) 1-Aminocyclopropane-1-carboxylic acid (ACPC) mimics the effects of glycine on the NMDA receptor ion channel. Eur.J.Pharmacol. 157 115 PMID: 2466672

Popik et al (1995) [3H]-1-Aminocyclopropanecarboxylic acid, a novel probe for strychnine-insensitive glycine receptors. Eur.J.Pharmacol. 291 221 PMID: 8719405

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Agonists

Keywords: ACPC, ACPC supplier, NMDA, Receptors, 0260, Tocris Bioscience

Citations for ACPC

Citations are publications that use Tocris products.

Currently there are no citations for ACPC.

Reviews for ACPC

There are currently no reviews for this product. Be the first to review ACPC and earn rewards!

Have you used ACPC?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.